Swedish researchers have completed a population cohort study and concluded that the use of the drug Rituximab, which is a monoclonal antibody to the B-cell antigen CD20, for treating multiple sclerosis is associated with an increased risk of developing inflammatory bowel disease.
The results of this study were officially published in the scientific journal JAMA Neurology.